The pTau 217 test measures phosphorylated tau, a protein linked to early Alzheimer’s changes in the brain. Elevated pTau can appear years or even decades before symptoms, making it an important screening tool for people starting in their 30s and beyond.

Early awareness gives you options — from current approved medications and/or lifestyle changes, which will prolong the progression of the disease.

Each test is all-inclusive and currently priced at $300–$325, making it one of the most accessible, non-invasive ways to assess Alzheimer’s risk early.

Not at this time — the ALZ Blood Test isn’t currently covered by private insurance, Medicare, or Medicaid. The all-inclusive cost is $300–$325, one of the lowest rates available for a non-invasive Alzheimer’s risk test.

Dementia is a broad term for memory and cognitive decline that interferes with daily life. Alzheimer’s disease is the most common form of dementia, responsible for most cases diagnosed in adults — both older adults and those in their 30s, 40s, and 50s with early-onset Alzheimer’s.

The first warning signs can appear as early as age 30 in cases of early-onset Alzheimer’s. Common symptoms include memory lapses, difficulty finding the right words, losing track of time or place, and getting lost in familiar areas. These changes may progress slowly, so paying attention to consistent memory or reasoning issues is important.

Alzheimer’s progresses through four main stages:

• Preclinical: Brain changes begin long before symptoms appear.

• Early (Mild): Memory problems and word-finding difficulties emerge — sometimes in people as young as their 30s.

• Moderate (Middle): Confusion, personality shifts, and greater difficulty performing daily tasks.

• Severe (Late): Loss of communication and independence.

When symptoms occur between ages 30 and beyond, the condition is referred to as early-onset Alzheimer’s disease.

In most cases, the cause isn’t fully understood. However, a mix of genetics, environment, and lifestyle factors likely play a role. Early-onset cases (age 30+) may have a stronger genetic component, especially among those with a family history of Alzheimer’s.

Having a family history of Alzheimer’s can increase your risk, particularly for early-onset forms of the disease. Still, genes are just one part of the equation — maintaining brain health and lifestyle choices are equally important.

There is currently no cure, but treatment options are improving. New approved medications and therapies aim to slow or modify disease progression, especially when started early. This is why identifying at-risk individuals is so valuable.